A new white paper was released by Siren Interactive on how to help those who may be considering compassionate use.
Requests for compassionate use of investigational drugs have increased dramatically in recent years, according to an FDA study reported in The Wall Street Journal.
Rare disease patients and caregivers are highly motivated to access treatment and skilled at using online petitions, blogs, video, social and traditional media to garner public support. Therefore, it’s especially important for companies that operate in this space to understand the issues and be prepared with a communications strategy and the policies that work to benefit all stakeholders. While there are guidelines for making decisions, an even more critical component is how biopharmaceutical companies communicate their policies to target audiences.
To read the paper in its entirety, Click Here.
To read more on compassionate use, you can view our new RARE Toolkit here. This toolkit will continue to be updated with new information.